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INTRODUCTION
Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disorder that affects 1-2% of the worldwide population with a prevalence that increases with age, especially in women. It is characterized by a persistent erosive synovitis that can lead to severe damage, disability and loss of function of the affected joints, and to chronic pain (1) . Current treatments aim at reducing inflammation to slow down the irreversible joint damage and to relieve inflammatory pain.
Recently it has been hypothesized that sensitization of the nociceptive system may contribute to the intensity and chronicity of the pain accompanying rheumatic diseases (2-4).
The transmission of pain relies on voltage-dependent Ca 2+ channels, in particular on Ca V 2.2, which is critically involved in nociceptor sensory transmitter release (5) and is considered a target to control osteoarthritis pain (6) . Ca V 2.2 can be specifically blocked by the ω ω ω ω-conotoxin MVIIA.
The synthetic form of the MVIIA conotoxin, commercialized as ziconotide or Prialt®, was approved in 2004 for the treatment of severe chronic pain associated with cancer, AIDS, inflammatory pain and neuropathies and cases of intractable morphine-insensitive pain.
Importantly, ziconotide acts synergistically with opioid analgesics without inducing tolerance or 4 addiction (7). However, its use requires intrathecal microinfusion pumps to minimize side effects on central nervous system channels, which can cause psychosis over a certain threshold.
Recent efforts to chemically re-engineer conotoxins have lead to more stable cyclic forms that can be administered orally rather than intrathecally (8) . If given orally, conotoxins may prove useful in managing pain in chronic inflammatory disorders like arthritis. However, the effect of Ca V 2.2-blockade on ongoing tissue inflammation in chronic inflammation or autoimmunity has so far not been addressed.
In the present study we investigated the contribution of Ca V 2.2 to the development of arthritis and the possible side-effects of targeting Ca V 2.2 in inflammatory pain management. To this end we employed pain-insensitive transgenic mice (Tg-MVIIA) that expressω ω ω ω-conotoxin MVIIA under control of the regulatory regions of the nociceptor-specific Scn10a gene and thus selectively block Ca V 2.2 channels in nociceptors (9) . In the context of our study it was essential to use a preclinical arthritis model that recapitulates the erosive inflammatory joint disease progression, and its autoimmune character, including the development of anti-citrullinated peptide antibodies (ACPA) that occur in RA patients (10) . ACPA are particularly interesting as they might be directly involved in the differentiation of osteoclast precursors into mature bone resorbing cells (11) .
Therefore, we chose the Antigen-and Collagen-induced arthritis (ACIA) model that unlike commonly used mouse models, effectively mimics the long lasting aspect of erosive synovitis along with autoimmune signs like the presence ACPA (12) .
The synovial joint inflammation is to a large extent driven by TNFα (13) , which also regulates the expression of RANKL (Receptor Activator of Nuclear factor Kappa-B Ligand; also known as OPGL, ODF and TRANCE), the main mediator of osteoclastogenesis and inflammatory bone resorption (14) . In RA, RANKL is expressed by synovial fibroblasts and activated synovial T cells.
It triggers osteoclastogenesis and bone loss (15, 16) , and promotes arthritis-induced joint destruction in the inflamed synovium (17) . Therefore we investigated RANKL expression in the inflamed joints of arthritic wt mice and pain-insensitive Tg-MVIIA mice.
We showed that Ca V 2.2 blockade effectively suppresses arthritis-induced pain but prolongs the ongoing inflammation leading to drastic joint deformation via the up-regulation of the osteoclast activator RANKL. Two weeks later arthritis was induced under inhalational isofluorane anaesthesia (Abbvie, Ludwigshafen, Germany) by intra-articular injection of 50 µg mBSA dissolved in 20 µl of PBS into the left knee joint cavity. Animals were analysed at sequential time points after arthritis induction reflecting different disease stages: acute arthritis (days 1-6), transition phase (day 10), early chronic (3-4 weeks) and late chronic arthritis (6-10 weeks).
MATERIALS AND METHODS:

Histological analysis and scoring
Knee joints were fixed in 4% buffered formaldehyde, decalcified with EDTA for 7-10 days, and embedded in paraffin. Serial sections (3-5 µm) were stained with HE for microscopic evaluation.
Scoring of the knee sections was performed in a blinded manner with examination of four sections per joint. A multi-parameter scoring system was used (see Table 1 ) and individual scores were sumed up.
Immunohistochemical analysis
Paraffin sections were deparaffinised, pretreated with 5% donkey serum, followed by an anti-RANKL antibody (polyclonal goat anti-mouse IgG, R&D Systems, Minneapolis), and a biotinylated donkey anti-goat antibody and streptavidin-conjugated horseradish peroxidase (SA-HRP) (both JacksonImmunoResearch, Newmarket, UK). As isotype control we used goat serum as primary antibody. Enzyme reactions were developed with the AEC + Substrate Kit (DAKO, Hamburg, Germany). RANKL expression was quantified using ImageJ (1.48v) software, by 6 measuring the % of the area of the cartilage stained positive for RANKL.
Spinal cord sections of the lumbar region innervating the knee joint (comprising nerve roots L4
and L5) were embedded in TissueTek O.C.T. (Sakura Finetek, Zoeterwoude, The Netherlands), snap frozen and cut using a microtome, dried and dehydrated with ice-cold acetone. For immunohistochemistry, cryosections were rehydrated in Tris buffer and stained with a rabbit antisubstance P antibody (Zymed/Invitrogen, CA), followed by a biotinylated donkey anti-rabbit antibody (JacksonImmunoResearch) and SA-HRP. As isotype control we used rabbit serum.
Enzyme reactions were developed as described above. (Fig. 1A ,B) specifically in nociceptive neurons (9) . Accurate expression of MVIIA in Tg-MVIIA mice was confirmed by RT-PCR (Fig. 1C) . Dorsal Root Ganglia (DRG), which contain the somata of nociceptive neurons, express MVIIA, Scn10a (BAC driver) and Cacna1b (alpha1B subunit of Ca V 2.2). MVIIA is also expressed in the knee of Tg-MVIIA mice at small but detectable amounts. Given that Ca V 2.2 is expressed not only in presynaptic terminals in the spinal cord, but also in the peripheral endings of nociceptors innervating the knee joint ( (18) and Fig. 1C ), we sought to test whether blocking of Ca V 2.2 channels in a cell-autonomous manner in nociceptors had an impact on knee joint inflammation in an autoimmune model of arthritis.
Detection of antigen-specific immunoglobulins
Joint inflammation in Antigen-Collagen-induced Arthritis (ACIA)
Knee joint inflammation was induced using our recently described model of combined Antigenand Collagen-Induced Arthritis (ACIA) ( Fig. 2A) . We evaluated the severity of inflammation and joint destruction by semiquantitative scoring of hematoxylin and eosin (HE) stained paraffin sections of the induced knee joint. As shown in Figure 2 and Table 1 , this protocol induces a strong initial inflammation (acute arthritis) characterized by fibrin exudates and a severe neutrophil influx into the synovial cavity within the first days after arthritis induction ( Transgenic mice expressing MVIIA show no deficits in joint capacitance after arthritis induction.
Since arthritis in humans often affects weight-bearing joints, we wanted to assess whether our ACIA joint inflammation model would evoke behavioural changes associated with pain, such as reduction in motor activity and differences in weight-bearing of the inflamed versus the noninflamed hind limb.
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The motor activity of wt and Tg-MVIIA show no weight-bearing asymmetry. This indicates that wt mice perveive pain that is maintained for the first 10 days after arthritis induction. During the chronic arthritis phase (at day 21), we observed no weight-bearing differences in wt mice indicating that pain or discomfort diminishes with time. This is in agreement with the histological findings in wt mice at this later stage (Fig. 2C) , that shows that the joint inflammation resolves during the chronic phase.
Remarkably, Tg-MVIIA mice showed no signs of weight-bearing asymmetry at any of the examined time points (Fig. 3B) ; they always bore the same weight on both, induced and noninduced, hind limbs despite ongoing knee inflammation and joint deformation (Fig. 2C ).
Several possible mechanisms that may account for this enhanced induced-arthritis upon Ca V 2.2-blockade could be proposed. Since Ca V 2.2 calcium influx triggers release of neurotransmitters and pro-inflammatory neuropeptides (i.e. substance P and calcitonin-gene related peptide (CGRP)), we analysed spinal cord sections at the level of the lumbar region innervating the knee for Substance P immunoreactivity. This analysis did not reveal apparent differences in the location or amount of substance P between both mouse groups (Fig. 3C ). This finding indicates that Ca V 2.2 neurotransmission at the spinal level might not be the only component in pain transmission. Since MVIIA is also expressed in the knee (Fig.1C) , we postulated that the analgesic effect of Ca V 2.2 blockade might take place locally in the joint. To test this hypothesis we injected soluble MVIIA in the inflamed knee of wt mice after induced arthritis. Interestingly mice no longer showed signs of pain, measured as weight-bearing deficits, both during the acute and transition phase (Fig. 3D, F Surprisingly, in contrast to the impressive difference in arthritis severity and joint deformation, the induction of ACPA (Anti-Citrullinated Peptide/Protein Antibodies), which are highly specific for RA, did not differ at any of the examined time points between wt or Tg-MVIIA mice ( These results indicate that Tg-MVIIA mice have no gross defects in immunologic tolerance and that the observed differences in disease chronicity and joint destruction between wt and Tg-MVIIA mice are indeed directly related to MVIIA blockade of Ca V 2.2 channels and reduced pain neurotransmission in these animals.
Elevated TNFα α α α and RANKL enhance inflammatory arthritis in pain-insensitive mice
We wanted to evaluate whether inhibition of nociceptive neurotransmission interferes with the expression of inflammatory mediators that are involved in inflammation and bone destruction in order to shed some light on the underlying mechanisms that entail the severe destructive phenotype in Tg-MVIIA mice.
Since TNFα is known to regulate the expression of RANKL, the main mediator of osteoclastogenesis and inflammatory bone resorption, we tested the ability of lymphocytes from 11 arthritic mice to produce TNFα upon restimulation. Cells from wt and Tg-MVIIA mice were isolated from the draining lymph nodes in different disease stages and stimulated in vitro with PMA and Ionomycin. Healthy untreated mice showed no difference in the ability of their CD4+ T cells to produce TNFα. However, during the acute phase, CD4+ T cells from Tg-MVIIA mice produced significantly more TNFα upon stimulation than cells from wt mice (Fig. 5A, p=0.006) .
Similarly, the levels of secreted IL-17 by T cells from Tg-MVIIA mice were significantly increased compared to wt in the transition phase (Fig. 5B, p=0.048 ). This suggests that increased proinflammatory cytokine production during the acute and transition phases of arthritis may contribute to the enhanced joint deformation in Tg-MVIIa mice.
Given the evidence on the involvement of RANKL in arthritic bone damage, we sought to compare RANKL expression in the chronic stage of our ACIA model. Indeed, immunostaining for RANKL was more prominent in the knee joints of Tg-MVIIA mice compared to wt mice (Fig. 5C,D, p=0.026). Our study for the first time indicates that analgesic treatment by Ca V 2.2 blockade enhances RANKL expression and joint destruction.
DISCUSSION
The studies presented here establish that the Ca V 2.2 antagonist, conotoxin MVIIA (ziconotide/prialt), effectively blocks inflammatory pain in a mouse model of induced arthritis, but also reveal that this blockade severely enhances the ongoing joint inflammation and deformation.
We show for the first time the deleterious impact of this type of analgesics on ongoing inflammation, suggesting that the activity of Ca V 2.2 channels in nociceptor neurons that innervate the injured joint is ultimately beneficial to re-establish the levels of proinflammatory cytokines and of the osteoclast-activator RANKL.
In arthritis, as in other inflammatory disorders, pain intensity does not necessarily reflect disease activity, since pain often persists in patients with adequately controlled inflammation. Indeed, inflammation in the joint causes peripheral and central sensitization, which is thought to be the basis of arthritic pain that appears as spontaneous pain and hyperalgesia (20 shown a rapid and sustained pain reduction in patients (27) , but long-term treatment has been reported to produce adverse effects in patients with advanced knee and hip osteoarthritis including peripheral edema, joint swelling and progressive osteoarthritis (28) . Similarly, in a combined study analysis 21.3% of the ziconotide-treated patients reported abnormal gait as an adverse effect, compared to only 2% in the placebo group (29) . This report also states that 9% of the ziconotide-group but none of the placebo-group developed arthralgia, i.e. joint pain. It is, at this point, unclear, if these effects are related to the intrathecal catheter or the actual compound.
The aim of our study was to model the blockade of Ca V 2.2 specifically in nociceptors during arthritis, rather than to mimic the actual situation of intrathecal administration of ziconotide. This is relevant in view of the future use of more stable cyclic forms of peptide conotoxins that can be administered orally rather than intrathecally (8) . In general, the present challenge in pain research is to identify orally active Ca V 2.2-inhibitors that block the channel in a voltagedependent manner (i.e. CRMP-2, NMED-160 and CNV2197944) to provide effective blocking only during high-frequency firing, which occurs in hypersensitive pain states (30) . These novel use-dependent channel blockers, with oral availability, are now reported to be undergoing clinical evaluation for analgesia in neuropathic and inflammatory pain (30, 31) .
Given the role of TNFα and RANKL in osteoclastogenesis, bone loss and joint destruction in arthritis (15) (16) (17) 32) we investigated these molecules in our ACIA model with Tg-MVIIA mice.
New biological therapies targeting TNFα, e.g. infliximab, adalimumab and etanercept have been successful in severe cases of rheumatoid arthritis (RA) where patients do not show an adequate response to conventional drugs (33) . RANKL is regulated by inflammatory cytokines including
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TNFα, dictates the differentiation, activity and survival of osteoclasts (34) and has been shown to be a marker and mediator of bone loss in rat models of inflammatory arthritis (32) .
Furthermore, postmenopausal osteoporosis and bone resorption have been reported to be successfully ameliorated by treatment with a monoclonal antibody to RANKL, denosumab (35) .
In our studies we observed for the first time that analgesic treatment, by Ca V 2. There is clear evidence that the local release of proinflammatory neuropeptides from peripheral terminals of afferent nerve fibers contributes to the development of neurogenic inflammation.
However, several studies report tissue-dependent differences regarding the mechanisms engaged by neuropeptides to initiate and maintain the inflammatory response in the target tissue (36, 38) . Upregulation of substance P and CGRP has been observed in joints after adjuvantinduced arthritis (39) . In contrast, a reduction in the substance P-containing fibres in the synovium has also been reported (40) , particularly in joints with heavy inflammatory infiltration, suggesting that the articular expression of nociceptive neuropeptides may be regulated differently at different stages of arthritis (41) . It is possible that the basal activity of Ca V 2.2 is necessary for the proper homeostasis of the system. For instance, it has been speculated that inhibition of Ca 2+ currents at sensory nerve endings may directly influence their sensitivity by changing the spike frequency adaptation (42, 43) . It is also possible that other signalling events may take place upon reduction of Ca V 2.2 calcium influx.
In conclusion, blocking Ca V 2.2 -mediated pain neurotransmission in our arthritis model amplified inflammatory events to such an extent that RANKL expression was enhanced, thus promoting osteoclast differentiation and activation and concomitant bone erosion and deformation. Despite 14 their obvious efficacy, the use of MVIIA peptide toxins and derivatives to alleviate pain in patients with inflammatory arthritis could be very harmful and ought to be assessed with extreme care.
Further insight into the role of Ca V 2.2 channel activity and hyperactivity in the regulation of the complex crosstalk between the immune system and the nociceptive pathways might provide safer analgesic alternatives for the treatment of this most common cause of disability.
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(C) RT-PCR analyses show MVIIA expression in DRG neurons and at lower levels in the knee of Tg-MVIIA mice and no expression in wt mice. Scn10a (used as BAC driver) is only detected in DRG cell bodies but not in the mouse knee. Cacna1b (encoding the α1B subunit of CaV2.2) was highly expressed in DRG neurons, and at lower levels in knee joint preparations of wt and Tg-MVIIA mice at comparable levels. Actb: actin b used as control. 192x82mm (300 x 300 DPI) , and cellular aggregates and synovial hyperplasia (in C). A multi-parameter grading system was used (see Table I ), where observation of the indicated individual signs of acute inflammation, chronic inflammation and joint destruction was assigned the indicated score (ranging form 1-3 for each parameter) and scores were summed up. The corresponding scores for wt and Tg-MVIIa mice are indicated in the graph. Statistics: Mann-Whitney-Test, *** p < 0,001, n = 6-16 mice per group. Scale bars: 400 µm. 218x299mm (300 x 300 DPI) show no weight-bearing asymmetry in the incapacitance test. Statistical differences are indicated by * between wt and Tg-MVIIA, and by # between wt and wt injected with MVIIA. n = 5-12, bars show the mean and SEM. 225x164mm (300 x 300 DPI) 
